Skip to content
  1. Home
  2. Peptide bioregulators
  3. Thymalin

Peptide bioregulators

Thymalin

Thymic bioregulator from the Khavinson family with long-term human mortality follow-up and immune-modulating effects.

Approved in Russia and Eastern Europe Peptide bioregulators Longevity Recovery & healing

Reviewed 2026-09-12
Full name
Thymic peptide bioregulator
Also known as
thymus peptide
Regulatory status
Approved in Russia and Eastern Europe; used in clinical practice

Origin

Isolated from thymic tissue extracts, developed by Vladimir Khavinson's laboratory at the St. Petersburg Institute of Bioregulation and Gerontology, part of the Russian bioregulation-therapy tradition emerging in the late 1980s-90s.

Mechanism

Stimulates differentiation of T lymphocyte precursors into mature CD4+/CD8+ T cells, reduces apoptosis of aging thymocytes, and modulates cytokine balance (lower IL-6/IL-1β, higher IL-10), normalizing immune homeostasis in aging.

Research summary

Evidence

A long-running Russian/Ukrainian cohort study (~266 elderly participants over 6-8 years) reported a 2.0-2.1-fold reduction in all-cause mortality in the Thymalin group versus controls, and 2.5-fold when combined with Epithalamin. Secondary outcomes included fewer acute respiratory infections and cardiovascular events. These are large effect sizes from small, Russian-led trials with limited Western replication, a caveat that applies to the whole bioregulator family.

Evidence tier: Approved in Russia and Eastern Europe — see the methodology note for how this is assessed.

Citations

Reported benefits

  • immune function restoration
  • reduced infection rates in elderly
  • reduced cardiovascular disease incidence
  • improved wound healing

Dosing protocols reported in the literature & community

These are protocols reported by compounding pharmacies, published trials, or self-experimentation communities — not a prescription. Start low, especially for anything new.

Reported dosing protocols
RouteReported protocol
Intramuscular or subcutaneous injectionTypical Russian protocol: 10-20 mg IM daily or every other day for 10-20 days, repeated every 6-12 months.

Side effects

  • rare mild local inflammation
  • rare transient fever
  • rare allergic reaction

Safety notes

Safety: Derived from animal thymic tissue, carrying a theoretical (undocumented) prion-disease risk. 15+ years of Russian clinical use report no serious adverse events. Not tested in pregnancy.
Community & reddit notes (anecdotal — not clinical evidence)

Available in Russia/Eastern Europe; some Western users order through offshore channels. Anecdotal reports of reduced illness frequency; no Western regulatory pathway exists.

Mixing compatibility

Pulled from a community-charted mixing-compatibility reference (anecdotal, clinic-use, and community-reported signals) — not a safety guarantee. Verify independently before combining anything.

Used together in wellness-clinic protocols

Reported as a combination to avoid